Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Equity Ratio (2016 - 2025)

Guided Therapeutics' Equity Ratio history spans 16 years, with the latest figure at 6.31 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 60.31% year-over-year to 6.31; the TTM value through Sep 2025 reached 6.31, down 60.31%, while the annual FY2024 figure was 3.55, 55.58% down from the prior year.
  • Equity Ratio for Q3 2025 was 6.31 at Guided Therapeutics, down from 5.82 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.68 in Q3 2022 and bottomed at 6.31 in Q3 2025.
  • The 5-year median for Equity Ratio is 3.38 (2021), against an average of 3.15.
  • The largest annual shift saw Equity Ratio skyrocketed 89.14% in 2021 before it crashed 183.95% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 2.67 in 2021, then skyrocketed by 67.91% to 0.86 in 2022, then plummeted by 166.25% to 2.28 in 2023, then tumbled by 55.58% to 3.55 in 2024, then crashed by 77.92% to 6.31 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Equity Ratio are 6.31 (Q3 2025), 5.82 (Q2 2025), and 5.2 (Q1 2025).